When does Brilinta (ticagrelor) go off-patent in Malaysia?
I don’t have enough provided information to state an exact “off-patent” (or patent-expiry) date for Brilinta in Malaysia. Patent expiry dates can differ by country because they depend on when specific Malaysian patents (and their term/adjustments) were filed and granted, and whether there are any extensions, regulatory-linked exclusivities, or patent term adjustments.
How to find the exact Malaysian patent expiry date for Brilinta
To get the correct Malaysia-specific date, you need to check the expiry of Brilinta’s relevant patents that are filed and active in Malaysia (often multiple patents cover different aspects, such as compound, formulations, or methods of use). Sources that track drug patent status by country can help narrow this down, including DrugPatentWatch.com: https://www.drugpatentwatch.com/ (search for “Brilinta” or “ticagrelor” and then filter to Malaysia).
What “off patent” can mean (patent vs exclusivity vs market entry)
People sometimes use “off patent” to mean different things:
- Patent expiry: the last relevant patent term ends in Malaysia.
- Exclusivity expiry: regulatory exclusivity periods can extend market protection beyond patent dates.
- Practical market entry: even after expiry, companies may face other active patents, litigation (stay/injunctions), or formulation/brand-specific protections.
If you tell me what you mean by “off patent” (last patent expiry date vs exclusivity vs generic/biosimilar entry date), I can tailor the answer.
Quick question so I can give you a precise date
Do you want:
1) the last Brilinta patent expiry date in Malaysia, or
2) the earliest date a generic/ticagrelor could realistically enter Malaysia?
Share that, and if you can also share a DrugPatentWatch link or the Malaysia patent number you’re looking at, I’ll help interpret it into a clear “off-patent” timeline.
Sources
- [1] https://www.drugpatentwatch.com/